• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一例与厄洛替尼相关的瘢痕性脱发。

A case of cicatricial alopecia associated with erlotinib.

作者信息

Yang Bo Hee, Bang Chan Yl, Byun Ji Won, Han Sung Hyub, Song Hee Jin, In Seung Gyun, Shin Jeong Hyun, Choi Gwang Seong

机构信息

Department of Dermatology, Inha University School of Medicine, Incheon, Korea.

出版信息

Ann Dermatol. 2011 Dec;23(Suppl 3):S350-3. doi: 10.5021/ad.2011.23.S3.S350. Epub 2011 Dec 27.

DOI:10.5021/ad.2011.23.S3.S350
PMID:22346276
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3276795/
Abstract

Erlotinib is a small-molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). Erlotinib has been used primarily to treat non-small cell lung cancer. In addition to its role in tumor cells, EGFR is also an important regulator of growth and differentiation in the skin and hair. Therefore, EGFR-TKIs have been associated with a number of cutaneous side effects including follicular acneiform eruptions, cutaneous xerosis, chronic paronychia, desquamation, seborrheic dermatitis, and hair texture changes. Herein, we report a rare case of a 61-year-old woman who was treated with erlotinib and experienced cicatricial alopecia.

摘要

厄洛替尼是一种表皮生长因子受体（EGFR）的小分子酪氨酸激酶抑制剂（TKI）。厄洛替尼主要用于治疗非小细胞肺癌。除了在肿瘤细胞中的作用外，EGFR也是皮肤和毛发生长及分化的重要调节因子。因此，EGFR-TKIs与多种皮肤副作用有关，包括毛囊性痤疮样皮疹、皮肤干燥、慢性甲沟炎、脱屑、脂溢性皮炎和发质改变。在此，我们报告一例罕见病例，一名61岁女性接受厄洛替尼治疗后出现瘢痕性脱发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5854/3276795/83ac8bab7c99/ad-23-S350-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5854/3276795/7f82595403ef/ad-23-S350-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5854/3276795/81930a93bfe9/ad-23-S350-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5854/3276795/83ac8bab7c99/ad-23-S350-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5854/3276795/7f82595403ef/ad-23-S350-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5854/3276795/81930a93bfe9/ad-23-S350-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5854/3276795/83ac8bab7c99/ad-23-S350-g003.jpg

相似文献

1
A case of cicatricial alopecia associated with erlotinib.一例与厄洛替尼相关的瘢痕性脱发。
Ann Dermatol. 2011 Dec;23(Suppl 3):S350-3. doi: 10.5021/ad.2011.23.S3.S350. Epub 2011 Dec 27.
2
A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
J Cutan Pathol. 2009 Dec;36(12):1303-7. doi: 10.1111/j.1600-0560.2009.01275.x. Epub 2009 Jun 9.
3
Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
J Am Acad Dermatol. 2006 Aug;55(2):349-53. doi: 10.1016/j.jaad.2005.12.016.
4
[Adverse cutaneous reactions to erlotinib].[厄洛替尼的皮肤不良反应]
Actas Dermosifiliogr. 2008 Jan-Feb;99(1):54-60.
5
Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.厄洛替尼相关皮肤毒性：转移性非小细胞肺癌患者的治疗策略。
J Am Acad Dermatol. 2013 Sep;69(3):463-72. doi: 10.1016/j.jaad.2013.02.025. Epub 2013 Apr 17.
6
Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment.厄洛替尼治疗后患者出现的毛囊周围黄瘤
Dermatol Ther (Heidelb). 2022 May;12(5):1281-1286. doi: 10.1007/s13555-022-00739-5. Epub 2022 May 4.
7
Substance P receptor blocker, aprepitant, inhibited cutaneous and other neurogenic inflammation side effects of the EGFR1-TKI, erlotinib.阿瑞匹坦是一种 P 物质受体拮抗剂，能抑制 EGFR1-TKI（厄洛替尼）引起的皮肤和其他神经源性炎症的副作用。
Mol Cell Biochem. 2020 Feb;465(1-2):175-185. doi: 10.1007/s11010-019-03677-7. Epub 2019 Dec 18.
8
Dermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: 'PRIDE' Complex.表皮生长因子受体抑制剂的皮肤副作用：“PRIDE”综合征
Indian J Dermatol. 2014 May;59(3):271-4. doi: 10.4103/0019-5154.131398.
9
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
10
Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor.
Acta Derm Venereol. 2004;84(1):23-6. doi: 10.1080/00015550310005898.

引用本文的文献

1
Cancer-Related Alopecia Risk and Treatment.癌症相关脱发的风险与治疗
Curr Treat Options Oncol. 2025 Jul 14. doi: 10.1007/s11864-025-01336-2.
2
JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia.JAK-STAT1作为表皮生长因子受体缺陷相关炎症和瘢痕性脱发的治疗靶点。
EMBO Mol Med. 2024 Dec;16(12):3142-3168. doi: 10.1038/s44321-024-00166-3. Epub 2024 Nov 9.
3
Cutaneous toxicities from targeted therapies used in oncology: Literature review of clinical presentation and management.

本文引用的文献

1
Folliculitis decalvans associated with erlotinib.与厄洛替尼相关的脱发性毛囊炎。
Clin Exp Dermatol. 2010 Dec;35(8):916-8. doi: 10.1111/j.1365-2230.2010.03852.x.
2
The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.表皮生长因子受体和血管内皮生长因子治疗在非小细胞肺癌治疗中的作用。
Clin Lung Cancer. 2010 Mar 1;11(2):82-90. doi: 10.3816/CLC.2010.n.011.
3
A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
肿瘤学中使用的靶向治疗的皮肤毒性：临床表现与管理的文献综述
Int J Womens Dermatol. 2021 Sep 28;7(5Part A):615-624. doi: 10.1016/j.ijwd.2021.09.009. eCollection 2021 Dec.
4
Dermatologic conditions in women receiving systemic cancer therapy.接受全身性癌症治疗的女性的皮肤病状况。
Int J Womens Dermatol. 2019 Nov 7;5(5):285-307. doi: 10.1016/j.ijwd.2019.10.003. eCollection 2019 Dec.
5
Management of Dermatologic Complications of Lung Cancer Therapies.肺癌治疗的皮肤并发症管理
Curr Treat Options Oncol. 2015 Oct;16(10):50. doi: 10.1007/s11864-015-0368-y.
J Cutan Pathol. 2009 Dec;36(12):1303-7. doi: 10.1111/j.1600-0560.2009.01275.x. Epub 2009 Jun 9.
4
Skin toxicities associated with epidermal growth factor receptor inhibitors.与表皮生长因子受体抑制剂相关的皮肤毒性。
Target Oncol. 2009 Apr;4(2):107-19. doi: 10.1007/s11523-009-0114-0. Epub 2009 May 19.
5
Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib.
Arch Dermatol. 2008 Nov;144(11):1524-5. doi: 10.1001/archderm.144.11.1524.
6
Etiology of cicatricial alopecias: a basic science point of view.瘢痕性脱发的病因学：从基础科学角度看
Dermatol Ther. 2008 Jul-Aug;21(4):212-20. doi: 10.1111/j.1529-8019.2008.00202.x.
7
Erlotinib-associated alopecia in a lung cancer patient.一名肺癌患者出现的厄洛替尼相关性脱发。
J Thorac Oncol. 2007 Dec;2(12):1136-8. doi: 10.1097/JTO.0b013e31815ba7f9.
8
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.与表皮生长因子受体抑制剂相关的皮肤副作用。
J Am Acad Dermatol. 2006 Oct;55(4):657-70. doi: 10.1016/j.jaad.2005.10.010.
9
Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
J Am Acad Dermatol. 2006 Aug;55(2):349-53. doi: 10.1016/j.jaad.2005.12.016.
10
Cutaneous side-effects of kinase inhibitors and blocking antibodies.激酶抑制剂和阻断抗体的皮肤副作用。
Lancet Oncol. 2005 Jul;6(7):491-500. doi: 10.1016/S1470-2045(05)70243-6.